The acquisition battle between global pharmaceutical giants Pfizer and Novo Nordisk over the bio company Metsera is heating ...

We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week’s best-performing ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Dow Jones Top Company Headlines at 1 AM ET: Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk | BDO's ... Novo Nordisk and Pfizer are showing some desperation in their gloves-off ...

Pfizer files lawsuit against Metsera and its directors & Novo Nordisk in the Delaware Court of Chancery for breach of merger agreement: New York Monday, November 3, 2025, 09:00 Hr ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Metsera currently has no products on the market, but is developing oral and injectable treatments for obesity and diabetes.

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, Palantir (NASDAQ:PLTR), Robinhood, Super Micro Computer, Qualcomm, ARM ...